Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous
system presenting with significant inter-and intraindividual heterogeneity. However, the …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Importance Early treatment initiation in multiple sclerosis (MS) is crucial in preventing
irreversible neurological damage and disability progression. The current assessment of …

Abstract Recombinant interferon (IFN) β-1b was approved by the US Food and Drug
Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in …

Neurodegeneration is one of the driving forces behind the pathogenesis of multiple sclerosis
(MS). Progression without activity, pathopsychological disturbances (cognitive impairment …

Introduction Immunotherapies for multiple sclerosis (MS) significantly decrease the risk of
new relapses. However, the chronic compartmentalized inflammation and …

Objective To describe the dynamics of brain volume loss (BVL) at different stages of
relapsing-remitting multiple sclerosis (RRMS), to describe the association between BVL and …

The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS)
are poorly understood. We used a new surface-based diffusion MRI processing tool to …

Background and Objectives No evidence of disease activity (NEDA)-4 has been suggested
as a treatment target for disease-modifying therapy (DMT) in relapsing-remitting multiple …

Background: Thalamic volume (TV) is a sensitive biomarker of disease burden of injury in
multiple sclerosis (MS) and appears to reflect overall lesion loads. Ibudilast showed …